Found: 350
Select item for more details and to access through your institution.
Neuromyelitis Optica Spectrum Disorder: Therapeutic Innovations and Complex Decision-Making.
- Published in:
- 2021
- By:
- Publication type:
- journal article
CSI: Multiple sclerosis. Tracing optic nerve involvement by standardized optical coherence tomography.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Management challenges for chronic dysimmune neuropathies during the COVID-19 pandemic.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Preventing long-term disability in CIDP: the role of timely diagnosis and treatment monitoring in a multicenter CIDP cohort.
- Published in:
- Journal of Neurology, 2024, v. 271, n. 9, p. 5930, doi. 10.1007/s00415-024-12548-1
- By:
- Publication type:
- Article
Proximal Charcot-Marie-Tooth Syndrome with Duplication on Chromosome 17p11.2.
- Published in:
- Annals of the New York Academy of Sciences, 1999, v. 883, n. 1, p. 469, doi. 10.1111/j.1749-6632.1999.tb08613.x
- By:
- Publication type:
- Article
Risk of Guillain-Barré syndrome following pandemic influenza A(H1N1) 2009 vaccination in Germany.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2014, v. 23, n. 11, p. 1192, doi. 10.1002/pds.3638
- By:
- Publication type:
- Article
The bradykinesia akinesia incoordination test (BRAIN TEST©), an objective and user-friendly means to evaluate patients with Parkinsonism.
- Published in:
- Movement Disorders, 2000, v. 15, n. 4, p. 641, doi. 10.1002/1531-8257(200007)15:4<641::AID-MDS1007>3.0.CO;2-2
- By:
- Publication type:
- Article
Die Corona-Pandemie und Multiple Sklerose: Impfungen und deren Implikationen für Patienten – Teil 1: Empfehlungen.
- Published in:
- Der Nervenarzt, 2021, v. 92, n. 12, p. 1276, doi. 10.1007/s00115-021-01155-4
- By:
- Publication type:
- Article
Die Corona-Pandemie und Multiple Sklerose: Impfungen und deren Implikationen für Patienten – Teil 2: Impfstofftechnologien.
- Published in:
- Der Nervenarzt, 2021, v. 92, n. 12, p. 1283, doi. 10.1007/s00115-021-01154-5
- By:
- Publication type:
- Article
Erratum zu: Ocrelizumab zur Behandlung der Multiplen Sklerose.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
Ocrelizumab zur Behandlung der Multiplen Sklerose.
- Published in:
- Der Nervenarzt, 2020, v. 91, n. 8, p. 722, doi. 10.1007/s00115-020-00937-6
- By:
- Publication type:
- Article
An innovative phase 2 proof‐of‐concept trial design to evaluate SAR445088, a monoclonal antibody targeting complement C1s in chronic inflammatory demyelinating polyneuropathy.
- Published in:
- Journal of the Peripheral Nervous System, 2023, v. 28, n. 2, p. 276, doi. 10.1111/jns.12551
- By:
- Publication type:
- Article
Analysis of relapse by inflammatory Rasch‐built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy.
- Published in:
- Journal of the Peripheral Nervous System, 2022, v. 27, n. 2, p. 159, doi. 10.1111/jns.12487
- By:
- Publication type:
- Article
Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review.
- Published in:
- Journal of the Peripheral Nervous System, 2020, v. 25, n. 3, p. 230, doi. 10.1111/jns.12402
- By:
- Publication type:
- Article
Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneuropathy And Treatment with Hizentra study.
- Published in:
- Journal of the Peripheral Nervous System, 2019, v. 24, n. 1, p. 72, doi. 10.1111/jns.12303
- By:
- Publication type:
- Article
Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.
- Published in:
- Journal of the Peripheral Nervous System, 2019, v. 24, n. 1, p. 48, doi. 10.1111/jns.12302
- By:
- Publication type:
- Article
A randomised, multi‐centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol.
- Published in:
- Journal of the Peripheral Nervous System, 2018, v. 23, n. 2, p. 108, doi. 10.1111/jns.12267
- By:
- Publication type:
- Article
International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome.
- Published in:
- Journal of the Peripheral Nervous System, 2017, v. 22, n. 2, p. 68, doi. 10.1111/jns.12209
- By:
- Publication type:
- Article
Fampridine- PR (prolonged released 4-aminopyridine) is not effective in patients with inflammatory demyelination of the peripheral nervous system.
- Published in:
- Journal of the Peripheral Nervous System, 2016, v. 21, n. 2, p. 85, doi. 10.1111/jns.12169
- By:
- Publication type:
- Article
Recombinant Acetylcholine Receptor Immunization Induces a Robust Model of Experimental Autoimmune Myasthenia Gravis in Mice.
- Published in:
- Cells (2073-4409), 2024, v. 13, n. 6, p. 508, doi. 10.3390/cells13060508
- By:
- Publication type:
- Article
The Molecular Basis for Remyelination Failure in Multiple Sclerosis.
- Published in:
- Cells (2073-4409), 2019, v. 8, n. 8, p. 825, doi. 10.3390/cells8080825
- By:
- Publication type:
- Article
B cell targeted therapies in inflammatory autoimmune disease of the central nervous system.
- Published in:
- Frontiers in Immunology, 2023, v. 14, p. 1, doi. 10.3389/fimmu.2023.1129906
- By:
- Publication type:
- Article
Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.991291
- By:
- Publication type:
- Article
The adenosinergic signaling in the pathogenesis and treatment of multiple sclerosis.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.946698
- By:
- Publication type:
- Article
Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial.
- Published in:
- Multiple Sclerosis Journal, 2024, v. 30, n. 2, p. 177, doi. 10.1177/13524585231216854
- By:
- Publication type:
- Article
Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 8, p. 945, doi. 10.1177/13524585231172145
- By:
- Publication type:
- Article
Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 14, p. 2177, doi. 10.1177/13524585221116269
- By:
- Publication type:
- Article
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 12, p. 1944, doi. 10.1177/13524585221102584
- By:
- Publication type:
- Article
Body mass index as a predictor of MS activity and progression among participants in BENEFIT.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 8, p. 1277, doi. 10.1177/13524585211061861
- By:
- Publication type:
- Article
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 3, p. 429, doi. 10.1177/13524585211024997
- By:
- Publication type:
- Article
Keep your eyes on the prize: Tackling breakthrough COVID-19 in MS patients.
- Published in:
- 2021
- By:
- Publication type:
- Editorial
Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.
- Published in:
- Multiple Sclerosis Journal, 2021, v. 27, n. 13, p. 2052, doi. 10.1177/1352458521988926
- By:
- Publication type:
- Article
Paradigm shifts: Early initiation of high-efficacy disease-modifying treatment in multiple sclerosis.
- Published in:
- 2021
- By:
- Publication type:
- Editorial
The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges.
- Published in:
- Multiple Sclerosis Journal, 2021, v. 27, n. 3, p. 479, doi. 10.1177/1352458520930620
- By:
- Publication type:
- Article
4-Aminopyridine is not just a symptomatic therapy, it has a neuroprotective effect – Commentary.
- Published in:
- Multiple Sclerosis Journal, 2020, v. 26, n. 11, p. 1312, doi. 10.1177/1352458520926458
- By:
- Publication type:
- Article
Alemtuzumab: Rare serious adverse events of a high-efficacy drug.
- Published in:
- Multiple Sclerosis Journal, 2020, v. 26, n. 6, p. 737, doi. 10.1177/1352458520913277
- By:
- Publication type:
- Article
Big data in MS—What can we learn from large international observational studies such as MSBase?
- Published in:
- 2020
- By:
- Publication type:
- Editorial
Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.
- Published in:
- Multiple Sclerosis Journal, 2019, v. 25, n. 12, p. 1605, doi. 10.1177/1352458518796675
- By:
- Publication type:
- Article
Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2019, v. 25, n. 9, p. 1273, doi. 10.1177/1352458519841829
- By:
- Publication type:
- Article
Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
- Published in:
- Multiple Sclerosis Journal, 2019, v. 25, n. 9, p. 1255, doi. 10.1177/1352458518789884
- By:
- Publication type:
- Article
Challenging a concept: Pulsed treatment regimen—No risk of PML?
- Published in:
- 2019
- By:
- Publication type:
- Editorial
Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.
- Published in:
- Multiple Sclerosis Journal, 2019, v. 25, n. 4, p. 565, doi. 10.1177/1352458518763089
- By:
- Publication type:
- Article
Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment.
- Published in:
- Multiple Sclerosis Journal, 2018, v. 24, n. 13, p. 1776, doi. 10.1177/1352458518771276
- By:
- Publication type:
- Article
Acute exacerbations after decades of non-active chronic multiple sclerosis.
- Published in:
- 2018
- By:
- Publication type:
- Case Study
ECTRIMS/ACTRIMS 2017: Closing in on neurorepair in progressive multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2018, v. 24, n. 6, p. 696, doi. 10.1177/1352458518768770
- By:
- Publication type:
- Article
Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta.
- Published in:
- Frontiers in Neurology, 2017, p. 1, doi. 10.3389/fneur.2017.00305
- By:
- Publication type:
- Article
Prominent T-Cell Responses against the Acetylcholine Receptor ε Subunit in Myasthenia Gravis.
- Published in:
- Neurology Research International, 2019, p. 1, doi. 10.1155/2019/1969068
- By:
- Publication type:
- Article
Retinal Damage in Multiple Sclerosis Disease Subtypes Measured by High-Resolution Optical Coherence Tomography.
- Published in:
- Multiple Sclerosis International, 2012, p. 1, doi. 10.1155/2012/530305
- By:
- Publication type:
- Article
Peripheral Facial Palsy: Etiology, Diagnosis and Treatment.
- Published in:
- European Neurology, 1999, v. 41, n. 1, p. 3, doi. 10.1159/000007990
- By:
- Publication type:
- Article
Safety of bridging antiplatelet therapy with the gpIIb-IIIa inhibitor tirofiban after emergency stenting in stroke.
- Published in:
- PLoS ONE, 2017, v. 12, n. 12, p. 1, doi. 10.1371/journal.pone.0190218
- By:
- Publication type:
- Article